Singapore Institute of Advanced Medicine (SGX:9G2) trimmed its net attributable loss to equity holders from continuing operations in fiscal first half ended Dec. 31, 2025 to SG$11.6 million from SG$12.6 million a year earlier, according to a Friday filing with the Singapore Exchange.
Loss per share came in at SG$0.0104 compared with SG$0.0135 in the year-ago period.
Revenue inched up 3% year over year to SG$8.3 million from SG$8.0 million.